FDA’s Yim Talks Biosimilars – In A Reddit AMA
Hints At Revisiting Suffix Naming Convention; ‘Never Say Never’ On CGT Competition
Executive Summary
In an “ask me anything” Q&A on Reddit, Sarah Yim – director of the FDA’s Office of Therapeutic Biologics and Biosimilars – offered some insights on the US biologics naming convention, biosimilar interchangeability, and the possibility of future competition on cell and gene therapies.